HR+/HER2- BREAST CANCER
Clinical trials for HR+/HER2- BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HR+/HER2- BREAST CANCER trials appear
Sign up with your email to follow new studies for HR+/HER2- BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Radiation boost added to standard care in fight against tough breast cancer
Disease control Not yet recruitingThis study is testing if adding a short, precise course of radiation (SBRT) to standard chemotherapy and immunotherapy before surgery works better for shrinking high-risk, hormone-positive breast cancer. About 302 patients will be randomly assigned to receive either the standard …
Matched conditions: HR+/HER2- BREAST CANCER
Phase: PHASE2 • Sponsor: First Affiliated Hospital of Wenzhou Medical University • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
New breast cancer drug challenges standard treatment in major trial
Disease control Not yet recruitingThis study compares a new drug combination (BGB-43395 plus letrozole) against current standard treatments for advanced breast cancer that has spread. It will involve over 1,000 adults with hormone-positive, HER2-negative breast cancer who haven't received prior treatment for thei…
Matched conditions: HR+/HER2- BREAST CANCER
Phase: PHASE3 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
New hope to stop High-Risk breast Cancer's return
Disease control Not yet recruitingThis trial is for people with a specific type of early breast cancer (ER+/HER2-) that is at a high risk of coming back. It will test if starting treatment with a new drug called elacestrant, with or without another standard drug, for 5 years is better at keeping the cancer away t…
Matched conditions: HR+/HER2- BREAST CANCER
Phase: PHASE3 • Sponsor: West German Study Group • Aim: Disease control
Last updated Mar 13, 2026 15:05 UTC
-
Could a simple test spare thousands of young women from harsh chemo?
Disease control Not yet recruitingThis study aims to see if a genetic test can safely guide treatment decisions for younger women with a common type of early breast cancer. It will compare the standard approach of giving chemotherapy to everyone against a personalized plan where some women receive only hormone th…
Matched conditions: HR+/HER2- BREAST CANCER
Phase: PHASE3 • Sponsor: UNICANCER • Aim: Disease control
Last updated Mar 03, 2026 14:05 UTC